Filtros de búsqueda

Lista de obras de Brian Druker

A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice

artículo científico publicado en 2009

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

artículo científico publicado en 2015

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2009

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

artículo científico publicado en 2007

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

artículo científico publicado en 2002

A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia

artículo científico publicado en 2007

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

artículo científico publicado en 2002

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

artículo científico publicado en 2012

A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis

artículo científico publicado en 2012

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib

artículo científico publicado en 2005

A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors

artículo científico publicado en 2010

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

artículo científico publicado en 2014

AMN107: tightening the grip of imatinib

artículo científico publicado en 2005

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

artículo científico publicado en 2009

Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells

artículo científico publicado en 2000

Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia

artículo científico publicado en 2012

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

artículo científico publicado en 2008

Activating alleles of JAK3 in acute megakaryoblastic leukemia

artículo científico publicado en 2006

Activation of a CrkL-stat5 signaling complex by type I interferons.

artículo científico publicado en 1999

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

artículo científico publicado en 2009

Age-related mutations and chronic myelomonocytic leukemia.

artículo científico publicado en 2015

All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells

artículo científico publicado en 2000

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

artículo científico publicado en 2008

An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma

artículo científico publicado en 2012

An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy

artículo científico publicado en 2008

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

artículo científico publicado en 2002

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia

artículo científico publicado en 2014

Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib

artículo científico publicado en 2006

Applying the discovery of the Philadelphia chromosome

artículo científico publicado en 2007

BCG-induced macrophages as suppressor cells

artículo científico publicado en 1983

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

artículo científico publicado en 2011

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

artículo científico publicado en 2010

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

artículo científico publicado en 2006

BCR-ABL-induced adhesion defects are tyrosine kinase-independent

artículo científico publicado en 2002

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

artículo científico publicado en 2014

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

artículo científico publicado en 2012

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein

artículo científico publicado en 2014

BIRB-796 is not an effective ABL(T315I) inhibitor

artículo científico publicado en 2005

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

artículo científico publicado en 2006

Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation

artículo científico publicado en 2007

Biochemical identification of a direct physical interaction between the CD4: p56lck and Ti(TcR)/CD3 complexes

scientific article published on 01 July 1991

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

artículo científico publicado en 2011

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells

artículo científico publicado en 2008

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

artículo científico publicado en 2010

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathwa

artículo científico publicado en 2013

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

artículo científico publicado en 2010

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery

artículo científico publicado en 2015

Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323

artículo científico publicado en 1998

Cbl-mediated ubiquitinylation and negative regulation of Vav.

artículo científico publicado en 2003

Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).

artículo científico publicado en 2004

Challenges and approaches to implementing master/basket trials in oncology

artículo científico publicado en 2019

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

artículo científico publicado en 2008

Characterization of murine JAK2V617F-positive myeloproliferative disease

artículo científico publicado en 2006

Chronic myelogenous leukaemia--new therapeutic principles.

artículo científico publicado en 2001

Chronic myelogenous leukemia.

artículo científico publicado en 2001

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status

artículo científico publicado en 2003

Chronic myeloid leukemia: current treatment options

artículo científico publicado en 2001

Circumventing Resistance to Kinase-Inhibitor Therapy

scientific article published on 01 June 2006

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

scientific article published in Nature Communications

Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

artículo científico publicado en 2010

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

artículo científico publicado en 2003

Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women

artículo científico publicado en 2016

Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl

artículo científico publicado en 2004

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

artículo científico publicado en 2005

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

artículo científico publicado en 2006

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine

artículo científico publicado en 2013

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

artículo científico publicado en 2010

CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors

scientific journal article

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

artículo científico publicado en 2014

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia

artículo científico publicado en 2012

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

artículo científico publicado en 2006

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

article

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

scientific article published on 24 September 2009

David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies

artículo científico publicado en 2003

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

artículo científico publicado en 2003

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

artículo científico publicado en 2004

Differential expression of novel tyrosine kinase substrates during breast cancer development

artículo científico publicado en 2007

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

artículo científico publicado en 2017

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.

artículo científico publicado en 2016

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression

artículo científico publicado en 2014

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

artículo científico publicado en 2004

Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma

artículo científico publicado en 2013

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

artículo científico publicado en 2020

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis

artículo científico publicado en 2004

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

artículo científico publicado en 2012

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

artículo científico publicado en 2002

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells

artículo científico publicado en 2001

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

scholarly article published in Cancer

Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia

artículo científico publicado en 2006

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

artículo científico publicado en 2015

FANCL ubiquitinates β-catenin and enhances its nuclear function

artículo científico publicado en 2012

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

artículo científico publicado en 2007

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

artículo científico publicado en 2007

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

artículo científico publicado en 2006

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

artículo científico publicado en 2013

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.

artículo científico publicado en 2014

Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.

artículo científico publicado en 2009

Gene expression changes associated with progression and response in chronic myeloid leukemia

artículo científico publicado en 2006

Generation of a large library of point mutations in polyoma middle T antigen.

artículo científico publicado en 1991

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

artículo científico publicado en 2019

Genomics: the breast cancer landscape.

artículo científico publicado en 2012

Granulocyte-macrophage colony-stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor-dependent hematopoietic cell line

artículo científico publicado en 1992

Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate

artículo científico publicado en 2008

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

artículo científico publicado en 2002

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience

artículo científico publicado en 2002

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

artículo científico publicado en 2004

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

artículo científico

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

artículo científico publicado en 2005

High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia

artículo científico publicado en 2008

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia

artículo científico publicado en 2008

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

artículo científico publicado en 2008

HitWalker: variant prioritization for personalized functional cancer genomics

artículo científico publicado en 2013

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

artículo científico publicado en 2010

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.

artículo científico publicado en 2016

Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis

artículo científico publicado en 2015

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles

artículo científico publicado en 2007

Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.

artículo científico publicado en 2005

Identification of the 70kD heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyrosine-containing proteins in T lymphocytes

artículo científico publicado en 1996

Imatinib (Gleevec) as a paradigm of targeted cancer therapies

artículo científico publicado en 2010

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

artículo científico publicado en 2013

Imatinib alone and in combination for chronic myeloid leukemia

artículo científico publicado en 2003

Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth

artículo científico publicado en 2013

Imatinib as a paradigm of targeted therapies

artículo científico publicado en 2004

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

artículo científico publicado en 2003

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

artículo científico publicado en 2002

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

artículo científico publicado en 2002

Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia

artículo científico publicado en 2012

Imatinib mesylate in the treatment of chronic myeloid leukaemia

artículo científico publicado en 2003

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

artículo científico publicado en 2008

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study

artículo científico publicado en 2012

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

artículo científico publicado en 2005

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

artículo científico publicado en 2005

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines

artículo científico publicado en 2003

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

artículo científico publicado en 2011

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

artículo científico publicado en 2002

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

artículo científico publicado en 2002

Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity

artículo científico publicado en 2008

Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance

artículo científico publicado en 2008

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

artículo científico publicado en 2002

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

artículo científico publicado en 2004

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

artículo científico publicado en 2002

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia

artículo científico publicado en 2013

Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.

artículo científico publicado en 1997

Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.

artículo científico publicado en 1998

Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells

artículo científico publicado en 1997

JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model

artículo científico publicado en 2015

Janet Rowley (1925-2013).

artículo científico publicado en 2014

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

artículo científico publicado en 2013

Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells

artículo científico publicado en 2002

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

artículo científico publicado en 2006

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

artículo científico publicado en 2003

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening

artículo científico publicado en 2012

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

scientific article published on 17 June 2019

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations

artículo científico publicado en 2021

Lessons learned from the development of imatinib

artículo científico publicado en 2004

Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization

artículo científico publicado en 2014

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

artículo científico publicado en 2010

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

artículo científico publicado en 2014

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

artículo científico publicado en 2005

MET receptor sequence variants R970C and T992I lack transforming capacity

artículo científico publicado en 2010

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

artículo científico publicado en 2002

Molecularly targeted therapy: have the floodgates opened?

artículo científico publicado en 2004

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

artículo científico publicado en 2006

Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target

artículo científico publicado en 2013

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry

artículo científico publicado en 2011

Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism

artículo científico publicado en 2015

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.

artículo científico publicado en 2007

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia

scientific article published on 29 November 2019

NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells

artículo científico publicado en 2020

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia

artículo científico publicado en 2011

No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).

artículo científico publicado en 2003

Ocular side-effects associated with imatinib mesylate (Gleevec).

artículo científico publicado en 2003

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML

artículo científico publicado en 2013

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia

artículo científico publicado en 2016

PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma

artículo científico publicado en 2014

Perspective: A Program to Improve Protein Biomarker Discovery for Cancer†

Perspectives on the development of a molecularly targeted agent

artículo científico publicado en 2002

Perspectives on the development of imatinib and the future of cancer research

artículo científico publicado en 2009

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

artículo científico publicado en 2004

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

artículo científico publicado en 2006

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

artículo científico publicado en 2009

Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes

artículo científico publicado en 2006

Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells

artículo científico publicado en 2007

Phosphorylation of src Family lck Tyrosine Kinase Following Interleukin-12 Activation of Human Natural Killer Cells

Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia

artículo científico publicado en 2006

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

artículo científico publicado en 2012

Ponatinib in refractory Philadelphia chromosome-positive leukemias

artículo científico publicado en 2012

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

scientific article published on 09 January 2014

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

artículo científico publicado en 2011

Practical management of patients with chronic myeloid leukemia receiving imatinib

artículo científico publicado en 2003

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

artículo científico publicado en 2020

Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics

artículo científico publicado en 2007

Protein tyrosine kinases and cancer

artículo científico publicado en 1997

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

artículo científico publicado en 2003

RAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytes

artículo científico publicado en 1997

RNAi screen for rapid therapeutic target identification in leukemia patients

scholarly article

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

artículo científico publicado en 2007

RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.

artículo científico publicado en 2004

Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease

artículo científico publicado en 2007

Recent advancements in the treatment of chronic myelogenous leukemia

artículo científico publicado en 2002

Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2

artículo científico publicado en 1997

SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl

artículo científico publicado en 2006

SRCircumventing imatinib resistance

artículo científico publicado en 2004

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

artículo científico publicado en 2001

ST1571: a paradigm for clinical trials of molecularly targeted agents

artículo científico publicado en 2001

STI571 (Gleevec) as a paradigm for cancer therapy

artículo científico publicado en 2002

STI571 as a targeted therapy for CML.

artículo científico publicado en 2003

STI571: a paradigm of new agents for cancer therapeutics

artículo científico publicado en 2002

STI571: targeting BCR-ABL as therapy for CML.

artículo científico publicado en 2001

Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs

artículo científico publicado en 2004

Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia

artículo científico publicado en 2015

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

artículo científico publicado en 2004

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

artículo científico publicado en 2003

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

artículo científico publicado en 2014

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

artículo científico publicado en 2020

Single particle quantum dot imaging achieves ultrasensitive detection capabilities for Western immunoblot analysis

artículo científico publicado en 2009

Specific targeted therapy of chronic myelogenous leukemia with imatinib

artículo científico publicado en 2003

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

artículo científico publicado en 2015

Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells

artículo científico publicado en 2008

Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway

artículo científico publicado en 2008

Survey of activated FLT3 signaling in leukemia

artículo científico publicado en 2011

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

scientific article published on 20 April 2006

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate

artículo científico publicado en 2006

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

artículo científico publicado en 2005

T cell activation-dependent association between the p85 subunit of the phosphatidylinositol 3-kinase and Grb2/phospholipase C-gamma 1-binding phosphotyrosyl protein pp36/38.

artículo científico publicado en 1995

TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins

artículo científico publicado en 2000

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

artículo científico publicado en 2011

TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2013

Targeted CML therapy: controlling drug resistance, seeking cure

artículo científico publicado en 2005

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2016

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation

scientific article published on 16 July 2019

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.

artículo científico publicado en 2011

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia

artículo científico publicado en 2010

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

artículo científico publicado en 2011

The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear

artículo científico publicado en 2014

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

artículo científico publicado en 2011

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

artículo científico publicado en 2013

The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1.

artículo científico publicado en 2002

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

artículo científico publicado en 2005

The NIH BD2K center for big data in translational genomics

artículo científico publicado en 2015

The PI3K/Akt1 pathway enhances steady-state levels of FANCL.

artículo científico publicado en 2013

The RING Finger Domain of Cbl Is Essential for Negative Regulation of the Syk Tyrosine Kinase

scientific article published in Journal of Biological Chemistry

The Related Adhesion Focal Tyrosine Kinase Differentially Phosphorylates p130Cas and the Cas-like Protein, p105HEF1 ⬇️

artículo científico publicado el 8 de agosto de 1997

The T cell receptor/CD3 complex and CD2 stimulate the tyrosine phosphorylation of indistinguishable patterns of polypeptides in the human T leukemic cell line Jurkat

artículo científico publicado en 1991

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

scientific article published on 02 May 2019

The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of the CrkL Adaptor Protein ⬇️

artículo científico publicado el 28 de noviembre de 1997

The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms

artículo científico publicado en 2006

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

artículo científico publicado en 2004

The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis.

artículo científico publicado en 2009

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

artículo científico publicado en 2002

The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation.

artículo científico publicado en 2001

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

artículo científico publicado en 2007

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia

artículo científico publicado en 2012

The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha

artículo científico publicado en 1998

Therapeutic drug monitoring in CML patients on imatinib

artículo científico publicado en 2007

Therapeutically Targetable ALK Mutations in Leukemia

artículo científico publicado en 2015

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis

artículo científico publicado en 2013

Translation of the Philadelphia chromosome into therapy for CML.

artículo científico publicado en 2008

Tyrosine phosphorylation of α tubulin in human T lymphocytes

artículo científico publicado en 1994

Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting

scientific article published on 20 June 2016

Will imatinib compromise reproductive capacity?

artículo científico publicado en 2011

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

artículo científico publicado en 2010

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway

artículo científico publicado en 2015

Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.

artículo científico publicado en 2005

c-CBL is not required for leukemia induction by Bcr-Abl in mice

artículo científico publicado en 2003

e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants?

article

hOCT 1 and resistance to imatinib

artículo científico publicado en 2005

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda